Novel Therapies for Essential Tremor

Essential Tremor Clinical Trial

Official title:

Novel Therapies for Essential Tremor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00018564
• Other study ID #: NEUD-048-00S
• Status: Completed
• Phase: Phase 3
• First received: July 3, 2001
• Last updated: January 20, 2009
• Start date: October 2000
• Est. completion date: September 2003

Study information

• Verified date: December 2004
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

This clinical research program is designed to evaluate medications as new treatments for essential tremor. Essential tremor is a common condition with few available therapies.

Description:

Each medication will be evaluated for effectiveness against tremor in a randomized, placebo-controlled, cross-over, double blind clinical research trial. Tremor will be assessed with accepted rating scales and accelerometry

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: September 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

1. Diagnosis of essential tremor.

2. Tremor rating scale score 3 or one or both upper extremities

3. Unsatisfactory response to primidone or to propanolol

4. Not taking tremor-inducing drug

5. Able to comply with visits

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Essential Tremor
• Tremor

Intervention

Drug:
• treatments for essential tremor

Locations

Country	Name	City	State
United States	VA Greater Los Angeles Healthcare System	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States,